ANETHOLTRITHION

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H8OS3
Molecular Weight	240.365
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

COC1=CC=C(C=C1)C2=CC(=S)SS2

InChI

InChIKey=KYLIZBIRMBGUOP-UHFFFAOYSA-N

InChI=1S/C10H8OS3/c1-11-8-4-2-7(3-5-8)9-6-10(12)14-13-9/h2-6H,1H3

HIDE SMILES / InChI

Description

Anethole trithione or anetholtrithione is a drug used in the treatment of dry mouth. Anethole trithione is a bile secretion-stimulating drug that restores salivation. It is listed in the U.S. National Cancer Institute's Dictionary of Cancer Terms as being studied in the treatment of cancer. Anethol has also been identified as a treatment for improving medium and severe dry eye symptoms. The mechanism of action for the chemopreventive and xerostomia properties have not been fully elucidated.

CNS Activity

Approval Year

Conditions

Conditions

Condition	Modality	Highest Phase	Product
Dry eye syndrome 21	Primary	Basic research	Unknown
Drug-induced xerostomia 1	Primary	Basic research	Unknown
Lung cancer 70	Preventing	Phase III 665	Unknown

C_max

Value	Dose	Analyte	Population
0.96 ng/mL	75 mg single, oral	ANETHOLTRITHION plasma	Homo sapiens
0.98 ng/mL	75 mg single, oral	ANETHOLTRITHION plasma	Homo sapiens
279.6 ng/mL	75 mg single, oral	ANETHOLTRITHION plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
1035.2 ng × h/mL	75 mg single, oral		ANETHOLTRITHION plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
4.03 h	75 mg single, oral	ANETHOLTRITHION plasma	Homo sapiens
3.78 h	75 mg single, oral	ANETHOLTRITHION plasma	Homo sapiens
4.5 h	75 mg single, oral	ANETHOLTRITHION plasma	Homo sapiens

Doses

Doses

Show entries

Dose	Population	Adverse events
25 mg 3 times / day multiple, oral Recommended	unhealthy, ADULT

Showing 1 to 1 of 1 entries

Previous1Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2,252 inducer 1,087 substrate 1,946	inhibitor 2,438 substrate 1,193	inhibitor 2,507 substrate 1,388	inhibitor 2,217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2,057 CYP1A2 2,153 CYP19A1 429	P-gp 2,052 CYP1A2 1,197 CYP1A1 389 CYP1B1 104 CYP2A6 626 CYP2C19 1,119 FMO3 77 CYP2E1 729 FMO1 25

Drug as perpetrator

Show entries

Target	Modality	Activity
CYP2D6 2,546	inhibitor 4,027	inconclusive [IC50 10.964 uM]
CYP3A4 2,633	inhibitor 4,027	inconclusive [IC50 10.964 uM]
CYP19A1 430	inhibitor 4,027	inconclusive [IC50 5.308 uM]
CYP3A4 2,633	inducer 1,966	no
CYP1A2 2,333	inhibitor 4,027	yes [IC50 0.9107 uM]

Showing 1 to 5 of 7 entries

Previous1 2Next

Drug as victim

Show entries

Target	Modality	Activity
P-gp 2,052	substrate 4,014	inconclusive
CYP2A6 626	substrate 4,014	likely
FMO3 77	substrate 4,014	likely
CYP1A1 389	substrate 4,014	major
CYP1A2 1,197	substrate 4,014	major